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Objective To determine whether bariatric surgery is effective for the treatment of nonalcoholic steatohepatitis (NASH)
in adolescence, we compared the efficacy of laparoscopic sleeve gastrectomy (LSG) with that of lifestyle interven-
tion (nonsurgical weight loss [NSWL]) for NASH reversal in obese adolescents.
Study design Obese (body mass index ≥ 35 kg/m2) adolescents (13-17 years of age) with biopsy-proven NAFLD
underwent LSG, lifestyle intervention plus intragastric weight loss devices (IGWLD), or only NSWL. At baseline
and 1 year after treatment, patients underwent clinical and psychosocial evaluation, blood tests, liver biopsy,
polysomnography, and 24-hour ambulatory blood pressure estimation.
Results Twenty patients (21%) underwent LSG, 20 (21%) underwent IGWLD, and 53 (58%) received lifestyle
intervention alone (NSWL). One year after treatment, patients who underwent LSG lost 21.5% of their baseline
body weight, whereas patients who underwent IGWLD lost 3.4%, and patients who underwent NSWL increase 1.7%.
In patients who underwent LSG, NASH reverted completely in all patients and hepatic fibrosis stage 2 disap-
peared in 18 patients (90%). After IGWLD, NASH reverted in 6 patients (24%) and fibrosis in 7 (37%). Patients
who received the NSWL intervention did not improve significantly. Hypertension resolved in all patients who un-
derwent LSG with preoperative hypertension (12/12) versus 50% (4/8) of the patients who underwent IGWLD (P = .02).
The cohort-specific changes in impaired glucose metabolism were similar: 100% (9/9) of affected patients who un-
derwent LSG versus 50% (1/2) of patients who underwent IGWLD (P = .02). LSG was also more affective in re-
solving dyslipidemia (55% [7/12] vs 26% [10/19]; P = .05) and sleep apnea (78% [2/9] vs 30% [11/20]; P = .001).
Conclusion LSG was more effective than lifestyle intervention, even when combined with intragastric devices,
for reducing NASH and liver fibrosis in obese adolescents after 1 year of treatment. (J Pediatr 2017;180:31-7).
See editorial, p 6
Morbid obesity affects about 5% of all adolescents in Westernized countries. Obesity poses an increased risk to youngindividuals of becoming morbidly obese adults and developing chronic diseases, such as type 2 diabetes, obstructivesleep apnea syndrome (OSAS), hypertension, and nonalcoholic fatty liver disease (NAFLD).1 In adolescents and adults,
NAFLD is the leading cause of chronic liver disease. Its spectrum ranges from simple steatosis to nonalcoholic steatohepatitis
(NASH). NASH includes inflammation and hepatocellular injury, and can progress to fibrosis, even at a young age.2
Lifestyle intervention is the first-line treatment for obesity and its comorbidities, but its efficacy is short term.3 In adults,
bariatric surgery produces long-lasting and stable weight loss leading to the partial or even complete reversal of chronic disease
associated with obesity.4-6 Recent evidence also suggests the reversal of NASH by bariatric surgery.7
AHI Apnea/hypopnea index
BIB BioEnterics Intragastric Balloon System
BMI Body mass index
HOMA-IR Homeostasis model assessment of insulin resistance
IGWLD Intragastric weight loss devices
LSG Laparoscopic sleeve gastrectomy
NAS Nonalcoholic fatty liver disease activity score
NASH Nonalcoholic steatohepatitis
NAFLD Nonalcoholic fatty liver disease
NSWL Nonsurgical weight loss
OGB Obalon Gastric Balloon
OSAS Obstructive sleep apnea syndrome
QoL Quality of life
T0 Baseline
T1 After 12 months
Teen-LABS Teen-Longitudinal Assessment of Bariatric Surgery
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In 2015, the position statement of the European Society for
Paediatric Gastroenterology, Hepatology and Nutrition sug-
gested bariatric surgery as a therapeutic option in morbidly
obese adolescents with NAFLD.8 However, data on its effi-
cacy for patients in this age group are lacking. The Teen-
Longitudinal Assessment of Bariatric Surgery (Teen-LABS), a
multicenter study aimed at investigating the efficacy of bariatric
surgery when performed in adolescence compared with adult-
hood, reported that NAFLD is highly prevalent in morbidly
obese adolescents by the time of surgery.9 Midterm results of
the Teen-LABS showed beneficial effects of this surgery on
weight loss maintenance, quality of life (QoL), and reversal of
major metabolic abnormalities. It did not provide data on liver
histology at postoperative follow-up.10
We report the early effects of laparoscopic sleeve gastrec-
tomy (LSG) on reversal of NASH of obese NAFLD patients.
Outcomes (including data on QoL, metabolic abnormalities,
and sleep apnea) of 2 contemporaneous cohorts of patients
who refused surgery and opted for lifestyle intervention alone
(nonsurgical weight loss [NSWL]) or in combination with
intragastric weight loss devices (IGWLD) are compared with
those after LSG.
Methods
Consecutive obese adolescents (n = 164; bodymass index [BMI]
≥ 35 kg/m2) with biopsy-proven NAFLD and failure to lose
≥10% of baseline body weight over the prior 6 months were
offered enrollment in this prospective pilot intervention study
to evaluate efficacy of LSG on liver histology; 93 patients entered
the study (Figure 1; available at www.jpeds.com).
According to the European Society for Paediatric Gastro-
enterology, Hepatology and Nutrition guidelines,8 patients
with BMI > 40 kg/m2 were offered LSG as the first surgical
option; lifestyle intervention plus IGWLD was offered as an
alternative. Patients with BMI between 35 and 40 kg/m2 or
lower, but having associated metabolic comorbidities, were
offered IGWLD as the first treatment option. IGWLD con-
sisted of balloons placed in the stomach for 3 months (Obalon
Gastric Balloon [OGB; Obalon Therapeutics Inc., Carlsbad,
California] in patients aged ≤ 14 years and/or with a BMI
between 35 and 38 kg/m2) or 6months (BioEnterics intragastric
balloon [BIB; Orbera, Apollo Endosurgery, Austin, Texas] in
patients >14 years old and/or with a BMI > 38 kg/m2). Those
patients who refused LSG or IGWLD had access to a lifestyle
intervention program (NSWL) consisting of a diet tailored to
the individual’s requirements and physical exercise.
Inclusion criteria included: age 13-17 years; BMI ≥ 35 kg/m2;
biopsy-proven NAFLD; failure to achieve 10% weight loss
using lifestyle intervention alone during the prior 6 months;
willingness and motivation to adhere to treatment recom-
mendations; clear understanding of risks and benefits deriv-
ing from medical treatment and surgery, including lifestyle
commitment in case of LSG; and dedicated family relatives
willing to serve as caregivers.
Exclusion criteria included: genetic obesity; any endocrine
or systemic disease, except metabolic abnormalities related
to obesity; severe gastroesophageal reflux disease and/or
esophagitis; large slidinghiatal hernia (>5 cm)orparaesophageal
hernia type III; psychiatric disorder; previous gastrointestinal
surgery; and use of recreational drugs and/or alcohol abuse
(>140 g/wk).11
At baseline (T0) and after 12months (T1) patients were clini-
cally assessed and underwent fasting biochemistry, oral glucose
tolerance test, liver ultrasound examination and biopsy,
polysomnography, 24-hour ambulatory blood pressure moni-
toring, and psychosocial evaluation according to protocols es-
tablished at the Bambino Gesù Children’s Hospital.3,12,13
In accordance with the recommendations of the Ethics
Committee at the Bambino Gesù Children’s Hospital that ap-
proved the study protocol (NCT 02564679), it was designed
as a prospective pilot investigation; patients were not as-
signed randomly to treatment groups.Written informed consent
was obtained from parents/legal guardians and patients.
Glucose metabolism was assessed by calculating the ho-
meostasis model assessment of insulin resistance (HOMA-
IR) as fasting insulin (mU/L) × fasting glucose (nmol/L)/22.5
and the ratio between the incremental areas under the curve
of glucose and insulin during the oral glucose tolerance test.
The polysomnography montage (Siesta; Compumedics,
Abbottsford, Australia) was equipped as described elsewhere
with simultaneousmonitoring of end-tidal carbon dioxide pres-
sures (Capnostream; Oridion, Needham,Massachusetts).12 The
apnea/hypopnea index (AHI) was defined as the number of
apnea and hypopnea events per hour of total sleep time. OSAS
was classified as mild (AHI ≥3 events/h), moderate (AHI 5-10
events/h), and severe (AHI ≥ 10 events/h).12
All patients underwent 24-hour ambulatory blood pres-
sure monitoring (Spacelab 90207; Spacelab Inc, Redmond,
Washington) equipped with an adequate cuff-size. Measure-
ments were recorded as elsewhere described and hyperten-
sion defined on the basis of reference standards adjusted for
sex and height.13
Liver biopsywas performed at T0 andT1 using an automatic
core biopsy device (Biopince, Amedic, Sweden) with an 18-G
needle under deep sedation and ultrasound guidance (Acuson
Sequoia C512 scanner equipped with a 15L8 transducer; Davis
Medical Electronics, Inc,Vista, California).14 A single patholo-
gist, blind to the treatment arm, reviewed and scored liver
histology. Steatosis (0-3), lobular inflammation (0-3), and
hepatocyte ballooning (0-2) were scored using the NAFLD
activity score (NAS), which ranged from 0 to 8 based on the
criteria of the NAFLD Clinical Research Network. The stage
of fibrosis was scored using a 5-point scale (stage 0-4). NASH
was defined as NAS ≥ 5.15
Intervention
Patients underwent nutritional counseling with registered di-
eticians at T0, T1, and throughout the follow-up period. Total
calories, micronutrient and macronutrient intake, and alcohol
consumption were estimated by 7-day dietary diary recall for
all patients. A balanced diet (40 kcal/kg/d, carbohydrates 55%,
proteins 15%, and lipids 30%)3 and aerobic physical activity
(30 min/d) were prescribed.
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OGB and BIB were offered on the basis of the patients’ age
and BMI.16 Because the OGB was smaller than the BIB device
(250 mL vs 600 mL), was more easily swallowed, and did not
require sedation, the OGB was placed in 7 younger patients
with BMIs of <38 kg/m2. The BIB was placed in either older
patients or younger patients with BMIs of ≥38 kg/m2.
The OGBwas usually swallowed and removed after 3 months
without tracheal intubation; an outpatient procedure was used
for both positioning and removal. A second OGB was added
after 1 month if the patient complained of persistent hunger
and/or to enhance weight loss. The risk of rupture and defla-
tion was rare. The BIB was positioned using endoscopy under
deep sedation during a hospital stay of ≤3 days and was
removed after 6 months using tracheal intubation during an
outpatient procedure. In the first 2 weeks after the BIB posi-
tioning, a semiliquid diet was prescribed. Risk of rupture and
deflation was extremely rare.
LSG was performed with a 5-trocar approach under general
anesthesia with endotracheal intubation. To greatly reduce sur-
gical risk, an optical trocar was used for the first access, avoid-
ing a blind access with a Veress needle. Complete dissection
of the greater curvature, 6 cm from the pylorus up to the gas-
troesophageal junction, was obtained using a radiofrequency
device (Ligasure; Medtronic, Minneapolis, Minnesota). The
gastric sleeve was calibrated with a 40F bougie using 60 mm
sequential firing (TristapleEndoGia; Medtronic). An intraop-
erative blue methylene test was performed to evaluate suture
line integrity and gastric pouch volume. A semiliquid diet was
prescribed for the first month after surgery, then a solid diet
was reintroduced at the end of month 1 after performing a
barium meal to evaluate both the gastric outlet and residual
gastric volume.17
Follow-Up
The multidisciplinary team evaluated the patients at baseline
and 1, 3, 6, and 12 months. Body weight, nutritional habits,
and physical activity were recorded during monthly meet-
ings with dieticians and nurses. Clinical examinations,
psychosocial questionnaires, blood tests, liver ultrasound and
liver biopsy, ambulatory blood pressure monitoring, and
polysomnography were performed at T0 and T1.
Statistical Analyses
Data were expressed as mean values ± SD or counts and per-
centages. Data distribution was evaluated by the Kolmogorov-
Smirnov test.Variables that were not normally distributed were
log transformed (eg, AHI) but reported as “not log trans-
formed” in the text for clarity. Because some patients in the
lifestyle intervention group dropped out of the study at months
6 (n = 14) or 12 (n = 17), the analysis was performed using the
last observation carried forward approach. Comparisons were
performed using the Student t test, ANOVA, the Fisher exact
test, and McNemar tests as appropriate.
Predictors of changes in OSAS and NASH after the inter-
vention were identified using the Pearson correlation and the
multiple linear regressions (stepwise method) with changes
of BMI z-score, weight, waist circumference, and insulin
resistance (by HOMA-IR) over time as independent vari-
ables. Data were analyzed using STATISTICA (version 2010;
Statistica, Chicago, Illinois). P ≤ .05 was considered significant.
Results
Of 164 patients, 93 (56.7%) met the inclusion criteria and
were enrolled in the study; 71 (43.3%) were excluded
(Figure 1). Enrolled and excluded patients did not differ in
anthropometrics, clinical characteristics, socioeconomic status,
or cognitive performance as estimated by IQ (data not shown).
Baseline anthropometrics, clinical, and metabolic character-
istics of the 93 enrolled patients (46.2% males) are described
in Table I (available at www.jpeds.com). Twenty patients (21%)
underwent LSG; 20 (21%) received intragastric devices plus
lifestyle intervention (7 OGB and 13 BIB, respectively). Fifty-
three patients (58%) opted for the lifestyle intervention with
no device (NSWL).
Perioperative (30 Days) and Follow-Up
Surgery Complications
Of the 7 patients, 3 (42.8%) required placement of a second
balloon 35 ± 6 days after the first procedure. In 2 cases,
positioning required endoscopy. No major perioperative com-
plications (gastric leak, perforation or erosion, bleeding, or
persistent vomiting) were recorded. The OGB was removed
endoscopically in all the patients under deep sedation after
13.5 ± 1 weeks by puncturing the balloon with a sclero-
therapy needle and grasping it with foreign body forceps. One
patient presented with asymptomatic deflation of 1 of the 2
balloons and that was evacuated spontaneously as confirmed
by abdominal radiography.
One patient developed persistent vomiting that resolved after
5 days of treatment with ondansetron (0.15 mg/kg IV up to
amaximum of 4 mg/d).All the gastric devices remained in place
for the planned period and there were no complications or
adverse events that required emergency removal. Balloons were
removed endoscopically under general anesthesia with endo-
tracheal intubation after 27.2 ± 4 weeks using accessories de-
signed specifically to deflate and remove the device.17
The mean postoperative hospital stay was 4.5 ± 1.5 days.
Nomajor perioperative complication was recorded.One patient
developed dysphagia that resolved completely after 15 days.
Only 1 girl required hospital readmission; she presented with
bronchopneumonia and pleural effusion 2 weeks after LSG
and was treated with IV antibiotics (amoxicillin-clavulanate
50 mg/kg/d maximum 3 g/d and clarithromycin 8 mg/kg/d
maximum 1 g/d).
LSG versus Lifestyle Intervention with and without
Intragastric Balloon: Follow-Up Data
All LSG and IGLWD patients regularly attended the follow-
up clinical appointments and underwent liver biopsy at T1.
In the NSWL group, 14 patients (26%) dropped out of the study
at 6 and 17 months at T1; 22 patients (41.5%) completed the
12-month follow-up and underwent liver biopsy (Figure 1).
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Liver Histology
In the LSG cohort the fibrosis score improved significantly after
surgery (Table II): all patients who underwent LSG (100%)
had stage 2 fibrosis at T0, but 10% had stage 2 fibrosis at T1
(P = .001). Frequencies of patients affected by steatosis and bal-
looning decreased from 55% to 10% for grade 2 steatosis and
from 40% to 0% for grade 2 ballooning (P = .001). NASH was
diagnosed in 30% of patients at T0 and disappeared in all
at T1.
In the nonsurgical cohorts (n = 73; IGWLD and NSWL
cohorts combined), 29 patients (40%) had stage 2 fibrosis at
baseline. Forty-two (57.5%) underwent follow-up biopsy. Of
the 29 patients with fibrosis at the baseline, 16 cases underwent
follow-up biopsy and fibrosis persisted in all as did inflam-
mation and ballooning (Figure 2).
In the entire study population, the reduction of NAS score
was correlated with the changes over time in body weight
(R2 = 0.36; b = 0.35; P < .001), BMI z-score (R2 = 0.54; b = 0.16;
P < .001), waist circumference (R2 = 0.55; b = 0.10; P < .001),
and HOMA-IR (R2 = 0.53; b = 0.38; P < .001).
Weight Loss, Metabolic Abnormalities, and QoL
Weight and BMI decreased significantly at T1 only after LSG
(by 21.5% and 20.6%, respectively). In the IGWLDcohort, they
decreased by 3.4% and 3.2%, but these changes were not
significant. In theNSWL cohort, the weight increased by 1.7%,
but the BMI decrease by 1.9%; in all cohorts there were no sig-
nificant differences at T1 in the heights (Figure 3; available at
www.jpeds.com).Table III shows follow-upmetabolic data of
3 cohorts, patients who underwent LSG versus other cohorts
(IGWLDandNSWL); at T2, the fasting insulin (P = .05), 2-hour
insulin (P = .03), 2-hour glucose (P = .05), and HOMA-IR
(P = .04) levels were significantly lower in the patients who
underwent LSG than in the other cohorts.
LSG was followed by a significant improvement or even re-
versal of hypertension, dyslipidemia, impaired glucose me-
tabolism, andOSAS (Table IV). Indeed, at T0,mild,moderate,
and severe OSAS were diagnosed, in 3 (15%), 4 (20%), and 2
(10%), respectively, patients with LSG. In contrast, at T1 it per-
sisted only in 2 patients (10%), one with mild and the other
with moderate OSAS (5%). AHI ameliorated in parallel with
the decrease of BMI z-score (R2 = 0.44;b = 0.26;P < .001), body
weight (R2 = 0.27; b = 0.14; P < .01) and waist circumference
(R2 = 0.39; b = 1.19; P = .01). OSAS did not ameliorate in the
nonsurgical groups.
Patients who underwent LSG experienced a significant im-
provement in their overall QoL score (mean values decreased
from 74.14 ± 12.66 to 86.18 ± 11.74; P = .05) and in the social
Table II. Liver histology in LSG versus nonsurgical group








n (%) n (%) n (%) n (%) n (%) n (%)
20 (100) 20 (100) 20 (100) 20 (100) 53 (100) 22 (41.5)
Steatosis
0 0 (-) 15 (75) .001 2 (10) 13 (65) .02 3 (5.7) 14 (63.6) .01
1 7 (35) 3 (15) 0.10 11 (55) 5 (25) .06 41 (77.3) 3 (13.7) .01
2 11 (55) 2 (10) .05 4 (20) 2 (10) 0.11 6 (11.3) 5 (22.7) 0.10
3 2 (10) 0 (-) .01 3 (15) 0 (-) .01 3 (5.7) 0 (-) .02
Inflammation
0 3 (15) 9 (45) .04 5 (25) 11 (55) .09 18 (33.9) 8 (36.8) 0.86
1 17 (85) 11 (55) .001 13 (65) 9 (45) 0.12 35 (66.1) 14 (63.6) 0.89
2 0 (-) 0 (-) — 2 (10) 0 (-) — 0 (-) 0 (-) —
Portal inflammation
0 0 (-) 6 (30) .04 9 (45) 11 (55) 0.88 22 (41.5) 5 (22.7) 0.36
1 20 (100) 14 (70) 0.21 9 (45) 9 (45) 0.65 27 (51) 13 (59.1) 0.45
2 0 (-) 0 (-) — 2 (10) 0 (-) — 4 (7.5) 4 (18.2) 0.13
Ballooning
0 0 (-) 16 (80) .01 5 (25) 13 (65) .03 27 (51) 14 (63.6) 0.39
1 12 (60) 4 (20) .001 12 (60) 6 (30) .04 20 (37.7) 3 (13.7) 0.21
2 8 (40) 0 (-) — 3 (15) 1 (10) 0.13 6 (11.3) 5 (22.7) 0.16
Fibrosis
0 0 (-) 0 (-) — 0 (-) 0 (-) — 0 (-) 0 (-) —
1 0 (-) 18 (90) .001 7 (35) 15 (75) .02 37 (69.8) 12 (54.5) 0.67
2 20 (100) 2 (10) .001 13 (65) 5 (25) .04 16 (30.2) 10 (45.5) 0.52
NAS
1 0 (-) 13 (66.5) .001 0 (-) 5 (25) — 0 (-) 3 (13.7) .01
2 0 (-) 4 (20) .04 1 (5) 6 (30) .05 16 (30.2) 3 (13.7) 0.14
3 3 (15) 1(5) 0.14 9 (45) 9 (45) 0.46 21 (39.6) 11 (50) 0.34
4 11 (55) 2 (10) .05 4 (20) 0 (-) — 10 (18.9) 0 (-) —
5 6 (30) 0 (-) — 6 (30) 0 (-) — 6 (11.3) 5 (22.6) 0.15
6 0 (-) 0 (-) — 0 (-) 0 (-) — 0 (-) 0 (-) —
7 0 (-) 0 (-) — 0 (-) 0 (-) — 0 (-) 0 (-) —
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(mean values decreased from 60.23 ± 19.91 to 72.46 ± 13.44,
P = .02), emotional (mean values decreased from62.47 ± 22.18
to 81.77 ± 16.22;P = .04), and physical functioning areas (mean
values decreased from 62.77 ± 23.56 to 84.12 ± 11.91; P = .01).
Lifestyle intervention did not affect the patients’ QoL.
Discussion
LSG was followed by improved NASH and reverted hepatic
fibrosis in 90% of cases. In the cohorts treated by lifestyle
intervention alone or combined with intragastric balloons to
favor weight loss, NASH persisted in one-half the patients
and fibrosis in one-third of patients after 1 year of treat-
ment. Histology ameliorated primarily in the IGWLD group.
In addition, LSG was followed by better results than NSWL
interventions in terms of improvement of QoL and meta-
bolic abnormalities. The ability to produce long-term weight
loss remains a key issue in morbid obese adolescents. In
the nonsurgical groups, weight loss at 1 year was minimal or
null. In the NSWL cohort, compliance was poor and >50%
were lost to follow-up.
Figure 2. The trends of liver histology at T0 and T1 in 3 groups. The trends of histological modifications is expressed as per-
centage (%).














Age (y) 16.71 (1.44) 14.13 (2.12) 14.67 (1.89) .06 17.63 (1.40) 15.32 (2.09) 15.05 (1.37) .04
Sex (M/F) 7/13 (35/65%) 8/12 (40/60%) 28/25 (52.83/47.17%) .10 7/13 (35/65%) 8/12 (40/60%) 8/14 (36.36/63.64) .24
Weight, kg 137.12 (14.89) 107.78 (16.23) 103.94 (7.44) .02 107.67 (11.08) 104.15 (14.65) 105.70 (6.92) .24
Height, cm 167.71 (1.59) 163.45 (1.67) 160.06 (1.8) .22 167.73 (1.14) 163.5 (1.66) 163.59 (1.24) .69
BMI, kg/m2 48.56 (4.15) 40.24 (5.02) 40.40 (3.55) .05 38.54 (3.51) 38.93 (4.67) 39.61 (3.71) .67
WC, cm 119.52 (11.93) 104.35 (7.32) 105.29 (7.65) .07 104.46 (13.44) 98.96 (7.22) 99.86 (11.57) .09
BMI z-score 2.99 (0.37) 2.77 (0.69) 2.89 (0.64) .10 2.12 (0.82) 2.21 (0.53) 2.41 (0.68) .10
SBP, mm Hg 123 (8) 112 (14) 117 (12) .21 116 (8) 113 (16.88) 114 (6.38) .44
DBP, mm Hg 68 (10) 69 (10) 65 (7) .11 71 (9) 66 (14.44) 64 (1.44) .56
AST, UI/L 30 (10) 38 (19) 34 (16) .10 22 (6) 25 (11.06) 32 (25.13) .06
ALT, UI/L 38 (15) 31 (11) 47 (10) .06 24 (10) 24 (16.68) 37 (14.43) .05
Uric acid, mg/dL 8 (1) 7 (1) 6 (2) .55 6 (1) 6 (1) 6 (1) .64
Total cholesterol, mg/dL 162 (29) 166 (21) 162 (25) .75 145 (20) 154 (19) 141 (26) .12
LDL cholesterol, mg/dL 103 (18) 120 (35) 100 (25) .11 92 (21) 96 (16) 94 (30) .35
HDL cholesterol, mg/dL 42 (10) 40 (10) 43 (7) .82 40 (10) 41 (9) 40 (14) .47
Triglycerides, mg/dL 123 (51) 100 (36) 115 (23) .33 95 (31) 93 (23) 105 (51) .16
Fasting glucose, mg/dL 85 (16) 85 (10) 82 (8) .79 78 (8) 86 (10) 84 (11) .78
Glucose-120', mg/dL 123 (20) 106 (19) 113 (21) .14 85 (17) 102 (18) 111 (21) .05
HbA1c, mmol/mol 39.41 (6.08) 34.80 (2.43) 32.90 (1.95) .56 34.16 (2.93) 34.41 (2.17) 32.54 (0.77) .84
Insulin, mU/L 32 (13) 28 (9) 25 (13) .41 16 (7) 20 (6) 24 (8) .05
Insulin -120', mU/L 187 (96) 120 (64) 151 (96) .04 74 (70) 99 (57) 103 (67) .03
C-peptide, ng/mL 3.48 (0.92) 2.12 (0.34) 2.26 (1.17) .24 2.18 (0.48) 2.24 (0.32) 2.09 (0.22) .46
HOMA-IR 6.75 (2.56) 5.93 (1.98) 5.84 (2.05) .06 3.14 (1.44) 4.80 (2.47) 5.46 (1.55) .04
AUC Insulin(0-120)/AUCGlucose(0-120) 1.23 (0.46) 0.91 (0.32) 0.85 (0.44) .09 0.99 (0.21) 0.87 (0.15) 0.77 (0.28) .65
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve; C-peptide, connecting peptide; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; Tot-C, total cholesterol; WC, waist circumference.
Data are presented as mean values ± SD.
*Were considered statistically significant at P ≤ .05 at ANOVA test.
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We investigated the effect of bariatric surgery on liver his-
tology in young patients. Biopsy-proven fatty liver was de-
tected in 59% of the 242 obese adolescents undergoing bariatric
surgery in the Teen-LABS.9 The study has not yet reported the
effect of surgery on abnormal liver histology. Studies of adult
patients showed resolution of NAFLD after LSG in 84 patients18
and amelioration of steatohepatitis and fibrosis in 109 mor-
bidly obese individuals with biopsy-proven NASH who lost
weight after either gastric banding or Roux-and-Y gastric
bypass.7 In the latter case series, 94% of patients with mild
NASH and 70% of those with severe NASH experienced NASH
remission. The NAS score decreased from 5 to 1, and fibrosis
was reduced in 33.8% of patients. Interestingly, 1 year after
surgery NASH persisted in patients who lost less weight.7
In our series, the best results in terms of NASH and fibro-
sis reversal were seen in the LSG cohort; these patients lost a
significant amount of excess weight and the changes in NAS
score paralleled their weight loss.
Several mechanisms might have produced the restitution
of liver histology after LSG. Reduction of visceral fat depots
after weight loss protects against the overflow of fatty acids to
the liver. Increased availability of fatty acids, in turn, is pivotal
to the pathogenesis of fatty liver causing mitochondrial
dysfunction and lipotoxicity.19 LSG leads to a reduction of the
triglyceride-rich lipoprotein–apoB-100 production rate and an
increase in the apoB-100 fractional catabolic rate.20 Gastric
surgery caused changes in the paracrine concentrations of
glucagon-like peptide-1 and serum bile acids. In patients who
underwent LSG, circulating insulin and glucagon-like peptide-1
concentrations increased soon after the meal. Glucagon-like
peptide-1 directly affects hepatocytes by activating genes in-
volved in fatty acid b-oxidation and insulin sensitivity.21,22 In
rats, bile acids increased after sleeve gastrectomy. Some bile acids
downregulate hepatic lipogenic and bile acid synthetic genes
that are responsible for the hepatic steatosis.23 Consistent with
the published literature,24 we recently described altered gut
microbiota in young patients with NAFLD,25 and LSG might
restore the physiological microflora as observed in experi-
mental murine models. All these factors probably contrib-
uted to the amelioration of hepatic insulin resistance. Indeed,
the HOMA-IR, a rough estimate of the hepatic insulin resis-
tance, decreased significantly after surgery.
Surgery was also followed by beneficial remission of hyper-
tension, the amelioration of dyslipidemia and OSAS. These
results, as well as the significant amelioration of the QoL score,
confirmed previous results.8,10,26
In the nonsurgical cohorts, the reversal of NASH and fi-
brosis was modest and occurred only in patients who lost
weight. There was no beneficial effect of lifestyle interven-
tion on QoL despite the constant psychological support that
was provided by the multidisciplinary therapeutic approach.
In this pilot study,we did not observe anymajor perioperative
complication in patients undergoing LSG or in those who re-
ceived intragastric balloons, probably owing to the long ex-
perience of our surgeons. Effectiveness of intragastric devices
in terms of weight loss may be questionable because the pro-
cedure did not induce long-term benefits. However, fibrosis
stage 2 was reduced and NAS score decreased in 50% of the
patients in the IGWLD cohort (Table II). Furthermore, a recent
meta-analysis of 5 studies in adolescents with 6-24 months of
follow-up demonstrated that LSG induces weight loss similar
to Roux-en-Y gastric bypass, with very few surgery-related com-
plications and no mortality.27
A number of medical, surgical, and public health organi-
zations endorse bariatric surgery in obese adolescents with
metabolic comorbidities (BMI ≥ 35 kg/m2 and ≥1 major
comorbidity or BMI≥ 40 kg/m2 and at least amild comorbidity)
as an effective treatment in patients who fail to lose weight after
lifestyle intervention.28 Nevertheless,most young patients have
still limited access to bariatric surgery because of ethical,
efficacy, and safety concerns.
Results of the present investigation are promising, but the
study was affected by limitations. It was a small pilot study
of consecutive patients treated by surgery or lifestyle inter-
vention; treatment was not assigned randomly. It is impossible
to design a randomized clinical trial comparing surgery versus
lifestyle because of the net superiority of the former, in terms
of weight loss, and the low retention to treatment of the
latter. Patients who opted for surgery were more complicated
than patients who refused; they probably felt their severe
and life-threatening obesity was an important condition. Pa-
tients in the IGWLD group experienced weight loss in the
first 1-6 months of the follow-up with some benefits to their
liver histology. Any further beneficial effect might have been
masked or abolished, however, by the weight regain after the
intragastric device removal.
LSG reverted steatohepatitis and reduced hepatic fibrosis
in morbidly obese adolescents with NAFLD 1 year after surgery.
It was also beneficial for resolving hypertension and amelio-
rating dyslipidemia andOSAS. In contrast, lifestyle intervention,
alone or in combination with IGWLD, was not able to induce
a sustained weight loss and therefore was less effective in
reverting liver histology and metabolic abnormalities.
Longitudinal and larger cohort studies are needed to compare
the effectiveness of bariatric surgery with that of lifestyle
intervention for preventing the progression of NAFLD,
Table IV. The trend of comorbidities at T0 and T1 in 3 groups
Hypertension (%) OSAS (%) Dyslipidemia (%) IGT (%)
T0 T1 IC 95% P T0 T1 IC 95% P T0 T1 IC 95% P T0 T1 IC 95% P
LSG 60 0 28.24 to 60 .005 45 15 2.44 to 30 .03 60 5 23.66 to 55 .001 25 0 −1.09 to 25 .05
IGWLD 45 40 −4.75 to 5 .97 30 20 −6.84 to 10 0.5 40 25 −6.23 to 15 .45 20 10 −6.84 to 10 .5
NSWL 39.62 22.72 5.66 to 16.9 .25 22.64 27.27 −5.01 to −4.63 .98 41.5 36.3 −6.22 to 5.2 .5 15.09 13.63 −4.3 to 2.27 .98
Bold values indicate statistically significant values and were considered statistically significant at P ≤ .05.
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early in its natural history, toward more severe forms of liver
derangement. ■
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Figure 1. Study flow diagram. Diagram displays enrollment and the follow-up procedures for each treatment group.
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Figure 3. The weight trends during follow-up in the 3 treatment groups. Mean weight value with SD were plotted for 3 groups.
Table I. Anthropometrics, clinical, and metabolic vari-
ables of the entire population
Baseline n = 93
Sex (M/F) 43/50 (46.23%/53.77%)
Age (y) 15.21 (1.88)
Weight, kg 118.31 (21.75)
BMI, kg/m2 43.16 (4.21)
WC, cm 110.96 (9.87)
BMI z-score 2.91 (0.65)
SBP, mm Hg 118 (11)
DBP, mm Hg 67 (9)
Hypertension, n (%) 20 (21.5%)
AST, UI/L 34 (13)
ALT, UI/L 40 (16)
Uric acid, mg/dL 6 (1)
Total cholesterol, mg/dL 164 (25)
LDL cholesterol, mg/dL 107 (23)
HDL cholesterol, mg/dL 42 (8)
Triglycerides, mg/dL 115 (37)
Dyslipidemia, n (%) 30 (32.3%)
Fasting plasma glucose, mg/dL 86 (12)
Plasma glucose 120', mg/dL 118 (29)
IGT, n (%) 11 (11.8%)
HbA1c, mmol/mol 36.47 (4.21)
Insulin, mU/L 29 (11)
Insulin -120', mU/L 152 (89)
C-peptide, ng/mL 2.88 (0.86)
HOMA-IR 6.16 (3.77)
AUC Insulin(0-120)/AUCGlucose(0-120) 0.87 (0.39)





NASH, n (%) 31 (90.32%)
Fibrosis ≥ 2 (n;%) 39 (67.34%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the curve;
C-peptide, connecting peptide; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL, high-
density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; SBP, sys-
tolic blood pressure; WC, waist circumference.
Data are presented as mean values ± SD.
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